Author:
MacGrogan G,Rudolph P,Mascarel I de,Mauriac L,Durand M,Avril A,Dilhuydy J M,Robert J,Mathoulin-Pélissier S,Picot V,Floquet A,Sierankowski G,Coindre J M
Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. Asano T, An T, Mayes J, Zwelling LA, Kleinerman ES (1996a) Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene. Biochem J 319 (Part 1): 307–313
2. Asano T, An T, Zwelling LA, Takano H, Fojo AT, Kleinerman ES (1996b) Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumour cells sensitises the cells to etoposide. Oncol Res 8: 101–110
3. Belembaogo E, Feillel V, Chollet P, Cure H, Verrelle P, Kwiatkowski F, Achard JL, Le Bouedec G, Chassagne J, Bignon YJ (1992) Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer 28A: 896–900
4. Berger JM, Gamblin SJ, Harrison SC, Wang JC (1996) Structure and mechanism of DNA topoisomerase II. Nature 379: 225–232
5. Bitran JD, Samuels B, Trujillo Y, Klein L, Schroeder L, Martinec J (1996) Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous haematopoietic progenitor cell support following standard-dose adjuvant chemotherapy. Clin Cancer Res 2: 1509–1513
Cited by
82 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献